Logo
x

Search category

Subscribe Now

NLRP3 Inhibitors

Novartis to Acquire IFM Tre for its Clinical and Preclinical Portfolio of NLRP3 Inhibitors for $1.5B

Novartis to Acquire IFM Tre for its Clinical and Preclinical Portfolio of NLRP3 Inhibitors for $1.5B

  • April 1, 2019
Genentech Acquires Jecure Therapeutics for its Preclinical Stage NLRP3 inhibitors

Genentech Acquires Jecure Therapeutics for its Preclinical Stage NLRP3 inhibitors

  • November 29, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.